Amneal Pharmaceuticals (AMRX) Price to Sales (2018 - 2026)

Amneal Pharmaceuticals has reported Price to Sales for 9 years, with the latest figure at 6.94 in Q2 2026.

• On a quarterly basis, Price to Sales rose 97.97% year-over-year to 6.94 in Q2 2026; TTM through Jun 2026 was 1.77, a 99.09% increase from a year earlier, with the FY2025 full-year figure at 1.31, up 49.46% from the prior year.
• Price to Sales was 6.94 for Q2 2026 at Amneal Pharmaceuticals, up from 5.49 in the prior quarter.
• The five-year high for Price to Sales was 6.94 in Q2 2026, with the low at 0.76 in Q1 2023.
• Average Price to Sales over 5 years is 3.06, with a median of 2.93 recorded in 2023.
• The sharpest annual moves came in 2023 and 2024: Price to Sales slumped 70.0% in 2023, then surged 272.6% in 2024.
• Over 5 years, Price to Sales stood at 0.99 in 2022, then jumped by 204.29% to 3.02 in 2023, then increased by 11.46% to 3.36 in 2024, then soared by 44.87% to 4.87 in 2025, then surged by 42.62% to 6.94 in 2026.
• The last three Price to Sales figures came in at 6.94 (Q2 2026), 5.49 (Q1 2026), and 4.87 (Q4 2025), per Business Quant data.